Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

1658 results about "Disulfide bond" patented technology

In chemistry, a disulfide bond is a covalent bond, usually derived by the coupling of two thiol groups. The linkage is also called an SS-bond or disulfide bridge. The overall connectivity is therefore R–S–S–R. The terminology is widely used in biochemistry. In formal terms, the connection is a persulfide, in analogy to its congener, peroxide, but this terminology is obscure and is no longer used.

Method for making multispecific antibodies having heteromultimeric and common components

The invention relates to a method of preparing heteromultimeric polypeptides such as bispecific antibodies, bispecific immunoadhesins and antibody-immunoadhesin chimeras. The invention also relates to the heteromultimers prepared using the method. Generally, the method provides a multispecific antibody having a common light chain associated with each heteromeric polypeptide having an antibody binding domain. Additionally the method futher involves introducing into the multispecific antibody a specific and complementary interaction at the interface of a first polypeptide and the interface of a second polypeptide, so as to promote heteromultimer formation and hinder homomultimer formation; and / or a free thiol-containing residue at the interface of a first polypeptide and a corresponding free thiol-containing residue in the interface of a second polypeptide, such that a non-naturally occurring disulfide bond is formed between the first and second polypeptide. The method allows for the enhanced formation of the desired heteromultimer relative to undesired heteromultimers and homomultimers.
Owner:GENENTECH INC

Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents

The present invention discloses a one-step process for the production of cytotoxic conjugates of maytansinoids and cell binding agents. Maytansinoids having a disulfide linker that bears a reactive moiety are linked to cell binding agents, such as antibodies, without prior modification of the cell binding agent. These conjugates are useful as therapeutic agents which are delivered specifically to target cells and are cytotoxic.
Owner:IMMUNOGEN INC

Chemical linkers and conjugates thereof

The present disclosure provides drug-ligand conjugates that are potent cytotoxins, wherein the drug is linked to the ligand through either a peptidyl, hydrazine, or disulfide linker. The disclosure is also directed to compositions containing the drug-ligand conjugates, and to methods of treatment using them.
Owner:ER SQUIBB & SONS INC

Bivalent IgY antibody constructs for diagnostic and therapeutic applications

This invention relates to the field of recombinant antibody technology. It provides novel recombinant IgY antibody constructs for diagnostic and therapeutical applications. The bivalent antibody constructs display a heterotetrameric or homodimeric format stabilized by disulfide bonds. The constant heavy chain domains CH2-CH4 are partly or completely of avian origin, whereas the VH, VL, CL, and CH1 domains as well as the hinge region may be of avian origin or derived from any other species. The invention allows to combine the advantages of IgY antibodies with those of established mammalian monoclonal antibodies. IgY antibody constructs comprising nonglycosylated IgY constant heavy chain domains allow to reduce unwanted interactions with C-type lectins, e.g., in human sera. Furthermore, chimeric IgY antibody containing mammalian VH, VL, CL, and CH1 domains as well as a mammalian hinge region provide a higher molecular stability than IgY antibodies in acidic conditions and, thereby, are especially suited for peroral therapeutic applications.
Owner:PLS DESIGN

Method for making multispecific antibodies having heteromultimeric and common components

The invention relates to a method of preparing heteromultimeric polypeptides such as bispecific antibodies, bispecific immunoadhesins and antibody-immunoadhesin chimeras. The invention also relates to the heteromultimers prepared using the method. Generally, the method provides a multispecific antibody having a common light chain associated with each heteromeric polypeptide having an antibody binding domain. Additionally the method further involves introducing into the multispecific antibody a specific and complementary interaction at the interface of a first polypeptide and the interface of a second polypeptide, so as to promote heteromultimer formation and hinder homomultimer formation; and / or a free thiol-containing residue at the interface of a first polypeptide and a corresponding free thiol-containing residue in the interface of a second polypeptide, such that a non-naturally occurring disulfide bond is formed between the first and second polypeptide. The method allows for the enhanced formation of the desired heteromultimer relative to undesired heteromultimers and homomultimers.
Owner:GENENTECH INC

Modified Antibody Constant Region

The present inventors succeeded in improving the antibody constant region to have increased stability under acid conditions, reduced heterogeneity originated from disulfide bonds in the hinge region, reduced heterogeneity originated from the H chain C terminus, and increased stability at high concentrations as well as in discovering novel constant region sequences having reduced Fcγ receptor-binding, while minimizing the generation of novel T-cell epitope peptides. As a result, the present inventors successfully discovered antibody constant regions with improved physicochemical properties (stability and homogeneity), immunogenicity, safety, and pharmacokinetics.
Owner:CHUGAI PHARMA CO LTD

Biodegradable cross-linked cationic multi-block copolymers for gene delivery and methods of making thereof

A biodegradable cross-linked cationic multi-block copolymer of linear polyethylenimine (LPEI) wherein the LPEI blocks are linked together by hydrophilic linkers with a biodegradable disulfide bond and methods of making thereof. The biodegradable cross-linked cationic multi-block copolymer may also contain pendant functional moieties which are preferably receptor ligands, membrane permeating agents, endosomolytic agents, nuclear localization sequences, pH sensitive endosomolytic peptides, chromogenic or fluorescent dyes.
Owner:CLSN LAB

Anti-IL-6 Receptor Antibody

InactiveUS20110245473A1Enhanced antigen-neutralizing activity and pharmacokineticsGood treatment effectCompound screeningApoptosis detectionHigh concentrationHinge region
The present inventors succeeded in discovering specific amino acid mutations in the variable region, framework region, and constant region of TOCILIZUMAB, and this enables to reduce immunogenicity risk and the heterogeneity originated from disulfide bonds in the hinge region, as well as to improve antigen binding activity, pharmacokinetics, stability under acidic conditions, and stability in high concentration preparations.
Owner:CHUGAI PHARMA CO LTD

Toxin peptide therapeutic agents

Disclosed is a composition of matter of the formula (X1)a—(F1)d—(X2)b—(F2)e—(X3)c  (I) and multimers thereof, in which F1 and F2 are half-life extending moieties, and d and e are each independently 0 or 1, provided that at least one of d and e is 1; X1, X2, and X3 are each independently -(L)f-P-(L)g-, and f and g are each independently 0 or 1; P is a toxin peptide of no more than about 80 amino acid residues in length, comprising at least two intrapeptide disulfide bonds; L is an optional linker; and a, b, and c are each independently 0 or 1, provided that at least one of a, b and c is 1. Linkage to the half-life extending moiety or moieties increases the in vivo half-life of the toxin peptide, which otherwise would be quickly degraded. A pharmaceutical composition comprises the composition and a pharmaceutically acceptable carrier. Also disclosed are a DNA encoding the inventive composition of matter, an expression vector comprising the DNA, and a host cell comprising the expression vector. Methods of treating an autoimmune disorder, such as, but not limited to, multiple sclerosis, type 1 diabetes, psoriasis, inflammatory bowel disease, contact-mediated dermatitis, rheumatoid arthritis, psoriatic arthritis, asthma, allergy, restinosis, systemic sclerosis, fibrosis, scleroderma, glomerulonephritis, Sjogren syndrome, inflammatory bone resorption, transplant rejection, graft-versus-host disease, and lupus and of preventing or mitigating a relapse of a symptom of multiple sclerosis are also disclosed.
Owner:AMGEN INC

Method for the production of polypeptides

The present invention relates to a novel method for the production of short chain polypeptides, including polypeptides having up to 3 disulfide bonds and / or structures rich in basic amino acid residues, and open structured short chain polypeptides, e.g. glucagon, glucagon like peptides and their functional analogues, in genetically modified yeast cells, said genetically modified yeast cells, and a method for the preparation of said yeast cells.
Owner:NOVO NORDISK AS

Single chain recombinant T cell receptors

A single chain T cell receptor (scTCR) comprising an a segment constituted by a TCR α chain variable region sequence fused to the N terminus of a TCR α chain constant region extracellular sequence, a β segment constituted by a TCR β chain variable region fused to the N terminus of a TCR β chain constant region extracellular sequence, and a linker sequence linking the C terminus of the α segment to the N terminus of the β segment, or vice versa, the constant region extracellular sequences of the α and β segments being linked by a disulfide bond, the length of the linker sequence and the position of the disulfide bond being such that the variable region sequences of the α and β segments are mutually orientated substantially as in native αβ T cell receptors. Complexes of two or more such scTCRs, and use of the scTCRs in therapy and in various screening applications are also disclosed.
Owner:IMMUNOCORE LTD +1

Hydrogel bioscaffoldings and biomedical device coatings

Bioscaffoldings formed of hydrogels that are crosslinked in situ in an infarcted region of the heart (myocardium) by a Michael's addition reaction or by a disulfide bond formed by an oxidative process are described. Each of the bioscaffoldings described includes hyaluronan as one of the hydrogel components and the other component is selected from collagen, collagen-laminin, poly-l-lysine, and fibrin. The bioscaffolding may further include an alginate component. The bioscaffoldings may have biofunctional groups such as angiogenic factors and stem cell homing factors bound to the collagen, collagen-laminin, poly-l-lysine, or fibrinogen hydrogel component. In particular, the biofunctional groups may be PR11, PR39, VEGF, bFGF, a polyarginine / DNA plasmid complex, or a DNA / polyethyleneimine (PEI) complex. Additionally, the hydrogel components may be injected into the infarct region along with stem cells and microspheres containing stem cell homing factors. The bioscaffolding may be formed on a stent or a cardiac medical device.
Owner:ABBOTT CARDIOVASCULAR

Hair Color Smoothing Compositions and Methods

Compositions, kits, and methods for rebuilding the disulfide bonds in hair that is damaged due to a hair coloring treatment are disclosed. The compositions contain one or more compounds that covalently crosslink at least two thiol groups in the hair. The compositions may be applied subsequent to a hair coloring treatment or simultaneously with a hair coloring treatment. Under normal hair washing conditions, the covalent crosslinks formed are not succeptable to reduction or hydrolysis. Use of the crosslinking compositions prevent the reversion of the hair's disulfide bonds to its reduced state, for at least one week, preferably at least three months, more preferably at least one year, most preferably at least greater than one year, after at least one application of the composition.
Owner:LIQWD

Non-woven keratin cell scaffold

A hydratable, highly absorbent keratin solid fiber or powder capable of absorbing a large weight excess of water may be produced by partially oxidizing hair keratin disulfide bonds to sulfonic acid residues and reacting the sulfonic acid residues with a cation. The neutralized suspension can be filtered, washed, and dried, leaving keratin solid which can be shredded into fibers and further ground into powder. Addition of water to the solid produces a hydrogel. The powder or hydrogel may be useful as an absorbent material, as a therapeutic for skin, or as an excipient. The keratin materials can be incorporated into nonwoven films. The hydrogel may be used as biocompatible viscoelastic filler for implant applications. Both the hydrogel and nonwoven materials are also suitable for use as tissue engineering scaffolds.
Owner:KERAPLAST TECH LTD +1

Fusogenic lipids and vesicles

Novel lipid compounds are provided that may be termed "pro-cationic" in that they are neutral or negatively charged until they are either brought into contact with cellular membranes or are internalized by cells. The lipids have a hydrophobic tail group and a hydrophilic head group, the head group incorporating both a positively and negatively charged region at physiological pH. The hydrophobic tail group is stably connected to the positive region of the head group which in turn is connected to the negative region by a disulfide bond that is susceptible to cleavage by membrane-bound and intracellular factors. Cleavage of the disulfide bond removes the negatively charged region from the head group resulting in a lipid that is cationic and therefor fusogenic with negatively charged cell membranes. Consequently, lipids of the invention are useful as components of liposomes that serve as vehicles for delivering pharmaceutical agents into cells with reduced toxicity.
Owner:IONIS PHARMA INC

Homogeneous Antibody Populations

InactiveUS20100226925A1Efficient and economic productionImprove propertiesNervous disorderAntipyreticMonoclonal antibodyHinge region
The present invention is generally directed to methods of producing an increase in the enrichment and / or recovery of preferred forms of monoclonal antibodies. More particularly, the invention relates to methods for eliminating disulfide heterogeneity in the hinge region of recombinant IgG2 antibody proteins.
Owner:AMGEN INC

Method for the preparation of a non-woven silk fibroin fabrics

A process for producing non-woven silk fiber fabrics comprises the following steps: a) obtaining silk fibroin, for example either from silk cocoons, or silk textiles or waste silk; b) removing the sericin layer covering the silk fibroin fibers, when present; c) breaking the disulfide bonds between heavy (350 kDa) and light (27 kDa) chains of silk fibroin in order to obtain the production of chain fragments which serve as a specific cellular recognition sites promoting the attachment and growth of cells, d) homogenising of the material resulting from step c).
Owner:CONSORZIO PER GLI STUDI UNIVRI

Drug Delivery Systems

The present invention relates to microparticles comprising a gel body, wherein the gel body comprises a synthetic polymer and a drug, wherein the microparticles have an average diameter in the range 40 to 1500 μm, wherein the polymer is cross-linked by groups comprising disulfide linkages and is in the form of a hydrogel.
Owner:BIOCOMPATIBLES UK LTD

Extruded gluten based pet chew bodies

A method of forming solid gluten-based pet chew is provided wherein a gluten mixture is heated to a maximum temperature of up to about 80° C. to create a substantially homogeneous and flowable mixture under extrusion processing conditions. The formulation includes from about 40-90% by weight of grain protein, from about 10-40% by weight plasticizer, and at least about 0.01 by weight of a reducing agent such as sodium bisulfite for cleaving disulfide bonds present in the grain protein. Dental health agents including an acidulent and a chelator are added to promote good dental health. Optional ingredients such as fillers, fiber, lubricant / mold release agents and colorants can also be used. The formulations can be processed in extrusion or injection molding equipment.
Owner:DERMAPET

Modified Chimeric superantigens and their use

A conjugate between a target-seeking moiety and a modified superantigen, characterized in that the superantigen is a wild-type superantigen (SA I) in which an amino acid residue in a superantigen region (region I) determining binding to TCR, preferably TCRVβ, and T cell activation have been replaced by another amino acid residue while retaining the ability to activate a subset of T cells.In preferred embodiment the modified superantigen is a chimer between at least two wild-type superantigens (SA I, SA II etc) characterized in that one or more amino acid residues in a region determining binding to TCR and T cell activation have been interchanged between various wild-type superantigens.A therapeutic method making use of modified / chimeric superantigens as defined in the preceding paragraphs.An antibody preparation in which the cysteine residues that provide for interchain disulfide bonds have been mutated so as to forbid interchain disulfide bridges, preferably to serine residues, for use as pharmaceutical.
Owner:ACTIVE BIOTECH AB

Macromolecule thiolated modified derivatives and cross-linking material thereof

The present invention discloses a macromolecular sulfydryl modified derivative with general formula (I) or (II) as well as corresponding dithio-bond cross-linking material and corresponding cross-linking material of sulfydryl reaction active cross linker. Wherein, R1 and R2 include alkylidene, substituted alkylidene, aromatic base, polyether polyols, etc. and R1 and R2 can have the same or different chemical structure; P refers to macromolecular compound residue including carboxyl in the side chain and the molecular weight of the macromolecular sulfydryl modified derivative is 10 to 5 million. The side-chain chemical structure of the macromolecular sulfydryl modified derivative with general formula (I) or (II) is flexible and changeable with notable advantages of adjustable performance, mild preparation conditions, high production rate, high modification and controllability. The cross-linking material of the macromolecular sulfydryl modified derivative provided by the present invention can be used to inhibit the attachment of cells and used as the matrix for cell adhesion and growth.
Owner:BIOREGEN BIOMEDICAL (CHANGZHOU) CO LTD

Self-healing polyurethane resin containing disulfide bond and preparation method thereof

InactiveCN105482065ARepair damageStrong performance controllabilitySelf-healingPolyester
The invention relates to self-healing polyurethane resin containing disulfide bond and a preparation method thereof. The polyurethane resin comprises, by weight parts, 10-30 parts of polyether or polyester polyol, 3-20 parts of polyisocyanates, 1-10 parts of chain extender containing the disulfide bond, 0.001-1 part of organic tin or tertiary amine catalyst and 50-80 parts of organic solvent. The method for preparing the self-healing polyurethane resin containing the disulfide bond comprises the steps of weighing raw materials, stirring, heating and performing dehydration for the polyether or polyester polyol under vacuum conditions, lowering the temperature to 85 DEG C or below, adding the polyisocyanates and the organic tin or tertiary amine catalyst, reacting, lowering the temperature to 50 DEG C or below, adding the organic solvent and the chain extender containing the disulfide bond, reacting and performing vacuum defoamation to obtain the self-healing polyurethane resin. The self-healing polyurethane resin heals by itself under the heating or ultraviolet (UV) light conditions, the required conditions are mild, the healing speed is high, the effect is good, the preparation method is simple and easy to control, and raw materials are goods of commercialized production and are cheap and easy to obtain.
Owner:DONGHUA UNIV

Self-molding permanent agent and method for proceeding free-rod and free-band type permanent

The present invention relates to a self-molding permanent agent and a method for proceeding free-rod and free-band type permanent, more particularly to a self-molding permanent agent comprising (a) a reducing composition containing a reducing agent reducing a disulfide bond of cystine on the hair and a molding stimulant spontaneously molding to fix a hair design; (b) a molding composition inducing to mold after reacting with the molding stimulant; and (c) a softening composition releasing the action of a molding stimulant, and a method for pressing a free-rod and free-band type permanent, which overcomes a disadvantage in the conventional method for pressing a permanent that needs to wear a curling device such as rods for a permanent (perm rod) or rubber band and improves to apply a wave set without a hair-curling device for a short time, since it has a self-molding feature.
Owner:KOREA RES INST OF CHEM TECH

Concatameric immunoadhesion

Disclosed are concatameric proteins comprising two soluble domains, in which the C-terminus of a soluble domain of a biologically active protein is linked to the N-terminus of an identical soluble domain or a distinct soluble domain of a biologically active protein. Also, the present invention discloses dimeric proteins formed by formation of intermolecular disulfide bonds at the hinge region of two monomeric proteins formed by linkage of a concatamer of two identical soluble extracellular regions of proteins involving immune response to an Fc fragment of an immunoglobulin molecule, their glycosylated proteins, DNA constructs encoding the monomeric proteins, recombinant expression plasmids containing the DNA construct, host cells transformed or transfected with the recombinant expression plasmids, and a method of preparing the dimeric proteins by culturing the host cells. Further, the present invention discloses pharmaceutical or diagnostic compositions comprising the dimeric protein or its glycosylated form.
Owner:MEDEXGEN

Nonwoven sheet and film containing water absorbent keratin

A hydratable, highly absorbent keratin solid fiber or powder capable of absorbing a large weight excess of water may be produced by partially oxidizing hair keratin disulfide bonds to sulfonic acid residues and reacting the sulfonic acid residues with a cation. The neutralized suspension can be filtered, washed, and dried, leaving keratin solid which can be shredded into fibers and further ground into powder. Addition of water to the solid produces a hydrogel. The powder or hydrogel may be useful as an absorbent material, as a therapeutic for skin, or as an excipient. The keratin materials can be incorporated into nonwoven films. Another use for the hydrogel is as a biocompatible viscoelastic filler for implant applications.
Owner:KERAPLAST TECH LTD +1
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products